Status:
COMPLETED
Study of Hepatitis C Virus (HCV) Nonstructural Protein 5a (NS5A) Inhibitor IDX719 in Healthy and HCV-Infected Participants (MK-1894-001)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Hepatitis C, Chronic
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
PHASE2
Brief Summary
The purpose of the study is to test the safety and tolerability of different doses of IDX719 to find the best dose for future studies. The study will also assess the pharmacokinetics of IDX719. No for...
Eligibility Criteria
Inclusion
- All Participants
- Is in good general health.
- Agrees to use double-barrier method of birth control for at least 90 days after the last dose of study drugs.
- HCV Participants
- Has documented GT1, GT2, or GT3 chronic HCV infection.
Exclusion
- All Participants
- Is pregnant or breastfeeding.
- HCV Participants
- Has received prior HCV treatment.
- Is co-infected with hepatitis B virus (HBV) and/or human immunodeficiency virus (HIV).
Key Trial Info
Start Date :
January 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2012
Estimated Enrollment :
130 Patients enrolled
Trial Details
Trial ID
NCT01508156
Start Date
January 1 2012
End Date
July 1 2012
Last Update
April 27 2015
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.